Evidence-based Anticancer Materia Medica for Pancreatic Cancer

摘要: Pancreatic cancer is a malignant neoplasm of the pancreas. Early ­detection difficult, as patients seldom exhibit disease-specific symptoms at early stages pancreatic cancer, resulting in late diagnosis. The majority cancers are, upon diagnosis, advanced and unresectable. has lowest survival rate amongst all malignancies, with 5-year less than 5%. current treatment for very limited ineffective. Palliative chemotherapy usually administered an attempt to prolong survivability improve quality life. Gemcitabine combination gemcitabine erlotinib are only FDA approved standard therapies unresectable cancer. Several gemcitabine-based have been studied none which shown any significant benefit over monotherapy. There no established second-line treatment. In effort efficacy reduce side-effects chemotherapy, targeted therapy become one main approaches. Erlotinib, tyrosine kinase inhibitor, when used increase survival. Herbal medicine commonly by Asia ameliorate disease. clinical studies PHY906, herbal formulation that centuries treat gastrointestinal ailments, high potential treating various cancers. PHY906 example ­polychemical affects not just one, but many targets. This multi-pronged approach brings new horizon therapy.